

Bibliography

1. Depression. Internet Geneva: World Health Organization. 2007. Cited 1 October 2007; Available at: http://www.who.int/mental_health/management/depression/definition/en/.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet*, 1997; 349(9064):1498-504.
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003; 289(23):3095-105.
4. Libro Verde. Mejorar la salud mental de la población. Hacia una estrategia de la Unión Europea en materia de salud mental. In: Commission of the European Communities; 2005. p. 484 final.
5. Haro JM, Palacin C, Vilagut G, Martinez M, Bernal M, Luque I, et al. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeD-Espana. *Med Clin (Barc)* 2006; 126(12):445-51.
6. Crespo D, Gil A, Porrás Chavarino A, Grupo De Investigación en Depresión y Psiquiatría de Enlace. Prevalencia de los trastornos depresivos en psiquiatría de enlace. *Actas Esp Psiquiatr* 2001; 29(2):75-83.
7. Barro Lugo S, Saus Arús M, Barro Lugo A, M. FM. Depresión y ansiedad en inmigrantes no regularizados. *Aten Primaria* 2004; 34(9):504.
8. Instituto Nacional de Estadística. Defunciones según la causa de muerte. Internet. Instituto Nacional de Estadística. 2007. Cited 1 October 2007; Available at: <http://www.ine.es>.
9. Subgrupos ATC y principios activos de mayor consumo en el sistema nacional de salud en 2005. *Inf Ter Sist Nac Salud* 2006; 30:42-9.
10. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). *Int Clin Psychopharmacol* 1997; 12(1):19-29.
11. Aragonés Benaiges E, Gutierrez Perez M, Pino Fortuny M, Lucena Luque C, Cervera Virgili J, I GE. Prevalencia y características de la depresión mayor y la distimia en atención primaria. *Aten Primaria* 2001; 27(9):623-8.
12. Aragonés E, Pinol JL, Labad A, Folch S, Melich N. Detection and management of depressive disorders in primary care in Spain. *Int J Psychiatry Med* 2004; 34(4):331-43.
13. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? *J Clin Psychiatry* 1999; 60 Suppl 7:4-9; discussion 10-1.
14. Aragonés E, Pinol JL, Labad A. The overdiagnosis of depression in non-depressed patients in primary care. *Fam Pract* 2006; 23(3):363-8.
15. Grupo VPM- SNS. Variaciones en la práctica médica de salud mental. Atlas var. práct. méd. sist. nac. salud 2007; in press.
16. Harman J, Edlund M, Fortney J. Disparities in the adequacy of depression treatment in the United States. *Psychiatr Serv* 2004; 55(12):1379-85.

17. Villava Quintana E, Caballero Martínez L. Estudio sobre el uso y seguimiento del tratamiento con antidepresivos realizado por los médicos de Atención Primaria. *SEMERGEN* 2006; 32(9):427-32.
18. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2006. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/01.
19. Kaiser Permanente Care Management Institute. Depression Clinical practice guidelines. Oakland (CA): Kaiser Permanente Care Management Institute; 2006 Mar. 196 p. .
20. Agree Collaboration. Evaluación de guías de práctica clínica. Instrumento AGREE. Internet. Biblioteca Josep Laporte; Osteba. 2001. Cited 1 October 2007; Available at:http://www.osanet.euskadi.net/r85-20319/es/contenidos/informacion/metodos_formacion/es_1207/adjuntos/8-1-5-1_agree_esp-2001.pdf
21. NICE. Depression: management of depression in primary and secondary care: National Clinical Practice Guideline number 23; 2004. December 2004.
22. Scottish Intercollegiate guidelines Network S. Forming Guidelines Recommendation. En: SIGN 50: A guideline developers' handbook: Scottish Intercollegiate guidelines Network; 2001.
23. Martínez-Sahuquillo M, Echevarría MC. Métodos de consenso. Uso adecuado de la evidencia en la toma de decisiones. «Método RAND/UCLA» *Rehabilitación (Madr)* 2001; 35(6):388-392.
24. Alberdi Sudupe J, Taboada O, Castro Dono C. Depresión. Guías clínicas. Fistera. 2003. Cited 1 October 2007. Available at: <http://www.fistera.com/guias2/depression.asp>
25. Geddes J, Butler R, Hatcher S, Cipriani A, Price J, Carney S, et al. Depression in adults. *Clin Evid* 2006(15):1366-406.
26. Ingram RE, Ritter J. Vulnerability to depression: cognitive reactivity and parental bonding in high-risk individuals. *J Abnorm Psychol.* 2000 Nov; 109(4):588-96.
27. Regier DA, Boyd JH, Burke JD, Jr., Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. *Arch Gen Psychiatry* 1988; 45(11):977-86.
28. Serby M, Yu M. Overview: depression in the elderly. *Mt Sinai J Med* 2003;70 (1):38-44.
29. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, et al. The MINI International Neuropsychiatric Interview (M.I.N.I.) A Short Diagnostic Structured Interview: Reliability and Validity According to the CIDI. *Eur Psychiatry* 1997; 12:224-31.
30. Ferrando L F-AL, Soto M, Bobes J, Soto O, Franco L, Gubert J. M.I.N.I. Mini International Neuropsychiatric Interview. Versión en español 5.0.0.DSM-IV. Instituto IAP, Madrid, 1998.
31. Kupfer DJ. Long-term treatment of depression. *J Clin Psychiatry* 1991; 52 Suppl:28-34.
32. World Health Organization. Tenth Revision of the International Classification of Diseases. ICD-10. Mental and Behavioural Disorders. Madrid: Meditor; 1992.

33. American Psychiatric Association. DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Barcelona: Masson; 2003.
34. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. *Am J Psychiatry* 2006; 163(1):115-24.
35. Hamalainen J, Kaprio J, Isometsa E, Heikkinen M, Poikolainen K, Lindeman S, et al. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. *J Epidemiol Community Health* 2001; 55(8):573-6.
36. Turner RJ, Lloyd DA. Stress burden and the lifetime incidence of psychiatric disorder in young adults: racial and ethnic contrasts. *Arch Gen Psychiatry* 2004; 61(5):481-8.
37. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H. Offspring of depressed parents: 20 years later. *Am J Psychiatry* 2006; 163(6):1001-8.
38. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry* 2000; 157(10):1552-62.
39. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Verdeli H, Pilowsky DJ, et al. Families at high and low risk for depression: a 3-generation study. *Arch Gen Psychiatry* 2005; 62(1):29-36.
40. Lieb R IB, Hofler M, Pfister H, Wittchen H. Parenteral major depression and the risk of depression and other mental disorders in offspring: a prospective-longitudinal community study. *Arch Gen Psychiatry* 2002; 59:365-74.
41. Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. *Am J Med Genet B Neuropsychiatr Genet* 2006;141(8):912-7.
42. Eccleston D, Scott J. Treatment, prediction of relapse and prognosis of chronic primary major depression. *Int Clin Psychopharmacol* 1991;6 Suppl 2:3-10.
43. Wilhelm K, Parker G, Dewhurst-Savellis J, Asghari A. Psychological predictors of single and recurrent major depressive episodes. *J Affect Disord* 1999; 54(1-2):139-47.
44. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. *Arch Gen Psychiatry* 2006;63(10): 1113-20.
45. Fogel J, Eaton WW, Ford DE. Minor depression as a predictor of the first onset of major depressive disorder over a 15-year follow-up. *Acta Psychiatr Scand* 2006;113(1):36-43.
46. Goodwin RD, Fergusson DM, Horwood LJ. Panic attacks and the risk of depression among young adults in the community. *Psychother Psychosom* 2004;73(3):158-65.
47. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. *Neurology* 2003; 60(8): 1308-12.
48. King M, Weich S, Torres F, Svab I, Maaroos H, Neeleman J, et al. Prediction of depression in European general practice attendees: the PREDICT study. In: *BMC Public Health*; 2006. p. 6(1):6.
49. Druss BG, Hoff RA, Rosenheck RA. Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults. *J Clin Psychiatry* 2000; 61(3):234-7; quiz 238-9.
50. Lecrubier Y. Is depression under-recognised and undertreated? *Int Clin Psychopharmacol* 1998;13 Suppl 5:S3-6.

51. Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. *Br J Gen Pract* 2007; 57(535):144-51.
52. Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2002; 136(10):765-76.
53. MacMillan HL, Patterson CJ, Wathen CN, Feightner JW, Bessette P, Elford RW, et al. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. *CMAJ* 2005; 172(1):33-5.
54. Gilbody SM, House A, Sheldon TA. Instrumentos de cribaje (screening) y detección de casos para la depresión. En: Oxford: Update Software Ltd; 2007.
55. Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. *BMJ* 2001; 322(7283):406-9.
56. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. *J Affect Disord* 2007; 101(1-3):27-34.
57. Nieto Rodríguez E, Vieta Pascual E. La conducta suicida en los trastornos afectivos. In: Ros Montalban S, editor. *La conducta suicida*. Madrid: Arán; 1998. p. 99-121.
58. Möller HJ. Suicide, suicidality and suicide prevention in affective disorders. *Acta Psychiatr Scand Suppl.* 2003; (418):73-80.
59. Rutz W. Preventing suicide and premature death by education and treatment. *J Affect Disord.* 2001; Jan; 62(1-2):123-9.
60. Gibb BE, Alloy LB, Abramson LY, Rose DT, Whitehouse WG, Hogan ME. Childhood maltreatment and college students' current suicidal ideation: a test of the hopelessness theory. *Suicide Life Threat Behav.* 2001; 31(4):405-15.
61. Sokero TP, Melartin TK, Rytala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. *Br J Psychiatry* 2005; 186:314-8.
62. Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, Goldberg PH, Grunebaum MF, Burke AK, et al. Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. *Am J Psychiatry* 2007; 164(1):134-41.
63. Dumais A, Lesage AD, Alda M, Rouleau G, Dumont M, Chawky N, et al. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. *Am J Psychiatry* 2005; 162(11):2116-24.
64. Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. *J Clin Psychiatry* 2005; 66(4):412-7.
65. Furukawa T, McGuire H, Barbui C. Dosis bajas de antidepresivos tricíclicos para la depresión (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus, 2007 Número 3*. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2003.
66. Moncrieff J, Wessely S, Hardy R. Placebos activos versus antidepresivos para la depresión (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus, 2007 Número 3*. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).

67. Arroll B, Macgillivray S, Ogston S, Reid I, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis. *Annals of Family Medicine* 2005; 3(5), p. 449-456.
68. Williams JW, Jr., Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. *Ann Intern Med* 2000; 132(9):743-56.
69. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. *J Clin Psychiatry* 2002; 63(4):331-6.
70. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. *Int Clin Psychopharmacol* 2003; 18(4):211-7.
71. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. *Int Clin Psychopharmacol* 2002; 17(3):95-102.
72. Ballesteros J, Callado LF, Gutierrez M. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. *J Clin Psychopharmacol* 2007; 27(2):219-21.
73. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. *CNS Drug Rev* 2004; 10(1):23-44.
74. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. *Ann Pharmacother* 2005; 39(11):1798-807.
75. Montgomery S, Ferguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. *J Clin Psychopharmacol* 2003; 23(1):45-50.
76. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. *J Clin Psychopharmacol* 2002; 22(4):393-9.
77. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetina versus otros tipos de farmacoterapia para la depresión (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus*, 2007 Número 3. Oxford: Update Software Ltd. Available at: <http://www.update-software.com>. (translated from The Cochrane Library, 2007 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.) 2007.
78. Gartlehner G, Hansen R, Thieda P, DeVaughn-Geiss A, Gaynes B, Krebs E, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Internet. Agency for Health Care Research and Quality, 2007. Cit ed 1 October 2007. Available at: http://effectivehealthcare.ahrq.gov/repFiles/Antidepressants_Final_Report.pdf.
79. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. *J Psychopharmacol* 2006; 20(1):91-6.
80. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants A comparative study of the efficacy of citalopram and reboxetine. *J Affect Disord* 2006; 95(1 3):119-123.

81. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: A double-blind study in patients with major depressive disorder. *J Clin Psychopharmacol* 2006; 26(2):121-127.
82. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. Timing of onset of antidepressant response with fluoxetine treatment. *Am J Psychiatry* 2000; 157(9):1423-8.
83. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-23.
84. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. *J Clin Psychiatry* 2005; 66(2):148-58.
85. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. *BMJ* 2007; 334(7587):242.
86. US Food and Drug Administration. Antidepressant use in children, adolescents, and adults. Internet. US Food and Drug Administration. 2004. Updated 2 May 2007, cited 1 October 2007; Available at: <http://www.fda.gov/cder/drug/antidepressants/default.htm>.
87. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005; 330(7488):385.
88. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-9.
89. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: A double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. *J Clin Psychopharmacol* 2006; 26(1):75-78.
90. Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. *Curr Med Res Opin* 2006; 22(9):1703-13.
91. Institute for Clinical Systems Improvement (ICSI), editor. Health care guideline: major depression in adults in primary care. S 9th ed. Bloomington, MN: Institute for Clinical Systems Improvement; (ICSI); 2004.
92. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. *Aust N Z J Psychiatry* 2004; 38(6):389-407.
93. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. *Lancet* 2003; 361(9358):653-61.
94. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. *Am J Psychiatry* 1998; 155(9):1247-53.
95. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. *Harv Rev Psychiatry* 1998; 5(6):293-306.
96. Gilaberte I, Montejo AL, de la Gandara J, Perez-Sola V, Bernardo M, Massana J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. *J Clin Psychopharmacol* 2001; 21(4):417-24.

97. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. *Am J Psychiatry* 2006; 163(9):1542-8.
98. Vallejo Ruiloba J. Consenso. Tratamiento de las depresiones. Barcelona: Ars Médica; 2005.
99. Menza M. STAR*D: the results begin to roll in. *Am J Psychiatry* 2006; 163(7):1123.
100. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006; 163(11):1905-17.
101. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. *Eur Arch Psychiatry Clin Neurosci* 2005;255(6):387-400.
102. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. *Arch Gen Psychiatry* 2002; 59(3):233-9.
103. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. *Br J Psychiatry* 1999; 175:12-6.
104. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. *Acta Psychiatr Scand* 1988; 78(6):676-83.
105. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. *Am J Psychiatry* 2006; 163(7):1161-72.
106. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. *Am J Psychiatry* 2006; 163(9):1531-41; quiz 1666.
107. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. *J Affect Disord* 2005; 89(1-3):1-11.
108. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993; 50(5):387-93.
109. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry* 2006; 163(9):1519-30; quiz 1665.
110. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. *J Clin Psychiatry* 2001; 62(6):448-52.
111. Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharmacol* 2006; 26(6):653-6.

112. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med* 2006; 354(12):1243-52.
113. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. *Depress Anxiety* 2006; 23(6):364-72.
114. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2007; 68(2):224-36.
115. Hamilton KE, Dobson KS. Cognitive therapy of depression: pretreatment patient predictors of outcome. *Clin Psychol Rev* 2002; 22(6):875-93.
116. Beck A, Rush A. *Cognitive therapy of depression*. New York: Guilford Press; 1979.
117. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. *Clin Psychol Rev*. 2006 Jan.; 26(1):17-31.
118. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol* 2006; 74(4):658-70.
119. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. *Arch Gen Psychiatry* 2005; 62(4):409-16.
120. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *N Engl J Med* 2000; 342(20):1462-70.
121. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. *J Consult Clin Psychol* 2000; 68(4):615-23.
122. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. *Am J Psychiatry* 2007; 164(5):739-52.
123. Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? *J Clin Psychiatry* 2005; 66(4):455-68.
124. Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. *J Consult Clin Psychol* 2005; 73(4):647-57.
125. Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. *Am J Psychiatry* 2002; 159(8):1354-60.
126. Klerman G, Weissman M, Rousanville B. *Interpersonal psychotherapy of Depression*. New York: Basic Books; 1984.
127. de Mello MF, de Jesus Mari J, Bacaltchuk J, Verdelli H, Neugebauer R. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. *Eur Arch Psychiatry Clin Neurosci* 2005; 255(2):75-82.

128. Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. *Am J Psychiatry* 2007; 164(5):761-7.
129. Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. *J Consult Clin Psychol* 1986; 54(2):196-202.
130. Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. *Eur Psychiatry* 2007; 22(1):9-15.
131. Pérez M, García J. Tratamientos psicológicos eficaces para la depresión. *Psicothema* 2001; 13(3):493-510.
132. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. *Can J Psychiatry* 2001; 46 Suppl 1:38S-58S.
133. Department of Veterans Affairs/Department of Defense (VA/DoD). Clinical practice guideline for the management of major depressive disorder in adults. Virginia: West Virginia Medical Institute; 2000.
134. Sociedad Española de Psiquiatría. Consejo español sobre la terapia electroconvulsiva (TEC), 1999. Cited 1 October 2007; Available at: <http://www.medicinainformacion.com/documentos/consensotec.pdf>.
135. Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. *Health Technol Assess* 2005; 9(9):1-156, iii-iv.
136. Tharyan P, Adams C. Terapia electroconvulsiva para la esquizofrenia (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus*, 2007. Número 3. Oxford: Update Software Ltd. Available at: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007. Issue 3. Chichester, UK: John Wiley & Sons, Ltd.), 2005.
137. UK ECT Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; 361(9360):799-808.
138. Rose D, Fleischmann P, Wykes T, Leese M, Bindman J. Patients' perspectives on electroconvulsive therapy: systematic review. *BMJ* 2003; 326(7403):1363.
139. Rubin EH, Kinscherf DA, Figiel GS, Zorumski CF. The nature and time course of cognitive side effects during electroconvulsive therapy in the elderly. *J Geriatr Psychiatry Neurol* 1993; 6(2):78-83.
140. Bhatia SC, Baldwin SA, Bhatia SK. Electroconvulsive therapy during the third trimester of pregnancy. *J Ect* 1999; 15(4):270-4.
141. Echevarria Moreno M, Martin Munoz J, Sanchez Valderrabanos J, Vazquez Gutierrez T. Electroconvulsive therapy in the first trimester of pregnancy. *J ECT* 1998; 14(4):251-4.
142. Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. *J ECT* 2003; 19(3):139-47.
143. Gould R, Clum G. A meta-analysis of self-help treatment approaches. *Clin Psychol Rev* 1993; 13:169-86.
144. Burns D. *Sentirse bien. Una nueva terapia para las depresiones*. Barcelona: Paidós; 1999.
145. Holdsworth N, Paxton R. *Managing anxiety and depression*. London: Mental Health Foundation; 1999.

146. Lewinsohn P, Forster R, Youngsen M. Control your depression. Alaska: Fireside; 1992.
147. Gregory R, Canning S, Lee T, Wise JC. Cognitive bibliotherapy for depression: a meta-analysis. *Prof Psychol* 2004; 35(3):275-9.
148. Salkovskis P, Rimes K, Stephenson D, Sacks G, Scott J. A randomized controlled trial of the use of self-help materials in addition to standard general practice treatment of depression compared to standard treatment alone. *Psychol Med* 2006; 36(3):325-33.
149. den Boer PCAM WD, Russo S, van den Bosch RJ. Paraprofesionales para el tratamiento de la ansiedad y los trastornos depresivos. In: *La Biblioteca Cochrane Plus*, 2007. Número 3. Oxford: Update Software Ltd. Available at: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007. Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
150. Houston TK, Cooper LA, Ford DE. Internet support groups for depression: a 1-year prospective cohort study. *Am J Psychiatry* 2002; 159(12):2062-8.
151. Tuesca-Molina R, Fierro Herrera N, Molineros Sosa A, Oviedo Martinez F, Polo Arjona Y, Polo Cueto J, et al. Los grupos de socialización como factor protector contra la depresión en personas ancianas. Baranquilla, Colombia. *Rev Esp Salud Publica* 2003; 77(5):595-604.
152. Cheung A, Chung H, Wong S, Chan W, Li H. Depression Support Group: Participants' Evaluation and Perceived Effects. *Hong Kong Pract* 2006; 28(1):14-23.
153. Knubben K, Reischies FM, Adli M, Schlattmann P, Bauer M, Dimeo F. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. *Br J Sports Med* 2007; 41(1):29-33.
154. Mather AS, Rodriguez C, Guthrie MF, McHarg AM, Reid IC, McMurdo ME. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. *Br J Psychiatry* 2002; 180:411-5.
155. Sjosten N, Kivela SL. The effects of physical exercise on depressive symptoms among the aged: a systematic review. *Int J Geriatr Psychiatry* 2006; 21(5):410-8.
156. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. *Am J Prev Med* 2005; 28(1):1-8.
157. Singh NA, Stavrinou TM, Scarbek Y, Galambos G, Liber C, Fiatarone Singh MA. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *J Gerontol A Biol Sci Med Sci* 2005; 60(6):768-76.
158. Mukaino Y, Park J, White A, Ernst E. The effectiveness of acupuncture for depression -a systematic review of randomised controlled trials. *Acupunct Med* 2005; 23(2):70-6.
159. Smith C, Hay P. Acupuntura para la depresión. (Revisión Cochrane traducida). In: *La Biblioteca Cochrane Plus*, 2007. Número 3. Oxford: Update Software Ltd. Available at: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007. Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2006.
160. Leo RJ, Ligot J. A systematic review of randomized controlled trials of acupuncture in the treatment of depression. *J Affect Disord* 2007; 97(1-3):13-22.
161. Allen JJ, Schnyer RN, Chambers AS, Hitt SK, Moreno FA, Manber R. Acupuncture for depression: a randomized controlled trial. *J Clin Psychiatry* 2006; 67(11):1665-73.
162. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of *Hypericum perforatum* L. *Pharmacopsychiatry* 1997; 30 Suppl 2:129-34.

163. National Prescribing Centre. St John's wort: is it effective in depression? In: MeReC Extra 2001.
164. FDA Public Health Advisory. Risk of drug interactions with St John'S Wort and indinavir and other drugs. Internet. Center for Drug Evaluation and Research, 2007. Cited 1 October 2007; Available at: <http://www.fda.gov/Cder/drug/advisory/stjwort.htm>.
165. Linde K, Mulrow C, Berner M, Egger M. Hierba de San Juan para la depresión. (Revisión Cochrane traducida). In: La Biblioteca Cochrane Plus, 2007. Número 3. Oxford: Update Software Ltd. Available at: <http://www.update-software.com>. (Translated from The Cochrane Library, 2007. Issue 3. Chichester, UK: John Wiley & Sons, Ltd.). 2007.
166. Werneke U, Horn O, Taylor DM. How effective is St John's wort? The evidence revisited. *J Clin Psychiatry* 2004; 65(5):611-7.
167. Costa Ribas C, Etxeberria Agirre A. Diseminación e implementación de una GPCInternet. A Coruña: Fisterra. January 2007. Access. 21 September 2007. Avilable at: <http://www.fisterra.com/guias2/FMC/implementacion.asp>.
168. Kaiser Permanente Care Management Institute. Depression Clinical Practice Guideline. Oakland (CA): Kaiser Permanente Care Management Institute; 2006.
169. Fochtman L, Gelenberg AJ. Guideline Watch for the Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Internet. 2nd. American Psychiatric Association. 2005. Cited 1 October 2007; Available at: http://www.psych.org/psych_pract/treatg/pg/MDD.watch.pdf.
170. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. *Am J Psychiatry* 2000; 157(4 Suppl):1-45.
171. Stevens S, Smith D, Ellis P. Coping with depression. Australian treatment guideline for consumers and carers Melbourne: Royal Australian and New Zealand College of Psychiatrists; 2005.
172. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961; 4:561-71.
173. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23:56-62.
174. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979;134:382-9.
175. Beck AT, Steer RAç, Brown G. BDI-II, Beck depression inventory: Manual 2nd ed. San Antonio, Texas: Harcourt 1996.
176. Conde V, Useros E. Adaptación castellana de la escala de evaluación conductual para la depresión de Beck. *Rev Psiquiatr Psicol Med Eur Am* 1975; 12(217-36).
177. American Psychiatric Association. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Association; 2000.
178. Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 1967; 6(4):278-96.
179. Miller IW, Bishop S, Norman WH, Maddever H. The Modified Hamilton Rating Scale for Depression: reliability and validity. *Psychiatry Res* 1985; 14(2):131-42.
180. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. *Acta Psychiatr Scand* 1981; 63(3):290-9.

181. Ramos-Brieva J, Cordero Villafafila A. Validación de la versión castellana de la escala. Hamilton para la depresión. *Actas Luso Esp Neurol Psiquiatr Cienc Afines* 1986; 14:324-34.
182. Bobes J, Bulbena A, Luque A, Dal-Re R, Ballesteros J, Ibarra N. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 ítems de la Escala de valoración de Hamilton para la evaluación de la depresión. *Med Clin (Barc)* 2003; 120(18):693-700.
183. Shelton R. Management of major depressive disorders following failure of antidepressant treatment. *Prim Psychiatry* 2006; 12(4):73-82.
184. Bobes J, Portilla M, Bascarán M, D'Saiz P, Bousoño M. Banco de instrumentos básicos para la práctica de la psiquiatría clínica. In: *Instrumentos de evaluación para los trastornos del humor 3ª ed.* Barcelona: Ars Medica; 2004. p. 53-57.
185. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. *Acta Psychiatr Scand Suppl* 1978 (271):5-27.
186. Lobo A, Chamorro L, Luque A, Dal-Re R, Badia X, Baro E. Validación de las versiones en español de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. *Med Clin (Barc)* 2002; 118(13):493-9.
187. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. *Arch Gen Psychiatry* 1991; 48(9):796-800.
188. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. *Arch Gen Psychiatry* 1991; 48(9):851-5.
189. Cipriani A, Malvini L, Furukawa TA, Barbui C. Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis. *J Clin Psychopharmacol.* 2007. Aug; 27(4):352-6.
190. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. *J Clin Psychiatry* 2001; 62 Suppl 16:5-9.
191. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. *J Psychiatr Res* 2004; 38(6):577-82.
192. Lecrubier Y. How do you define remission? *Acta Psychiatr Scand Suppl* 2002 (415):7-11.
193. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. *Jama* 2003; 289(23):3152-60.
194. Keller MB. Remission versus response: the new gold standard of antidepressant care. *J Clin Psychiatry* 2004; 65 Suppl 4:53-9.
195. Sluzki CE. Process, structure and world views: toward an integrated view of systemic models in family therapy. *Fam Process* 1983; 22(4):469-76.
196. Feixas G, Miró M. Aproximaciones a la psicoterapia: Una introducción a los tratamientos psicológicos. Barcelona: Paidós; 1993.
197. Sinelnikoff N. *Las psicoterapias. inventario crítico.* Barcelona: Herder; 1999.

198. Bertalanffy LV. Teoría General de los sistemas. Fundamento, desarrollo, aplicaciones. Mexico: Fondo de cultura económica; 1976.
199. Watzlawick P. Pragmatics of Human Communication: A Study of Interactional Patterns, Pathologies, and Paradoxes New York: Norton; 1967.
200. Pérez M, Fernández J, Fernández C, Amigo I. Guía de tratamientos psicológicos eficaces I. Barcelona: Pirámide; 2003.
201. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46(11):971-82; discussion 983.
202. Andersson G, Bergström J, Holländare F, Ekselius L, Carlbring P. Delivering Cognitive Behavioural Therapy for Mild to Moderate Depression via the Internet: Predicting Outcome at 6-Month Follow-Up. Verhaltenstherapie 2004; 14:185-89.